De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Alphamab Oncology Beheer

Beheer criteriumcontroles 2/4

De CEO Alphamab Oncology's is Ting Xu, benoemd in Nov2008, heeft een ambtstermijn van 15.92 jaar. De totale jaarlijkse vergoeding van { bedraagt CN¥ 6.88M, bestaande uit 95.2% salaris en 4.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 33.05% van de aandelen van het bedrijf, ter waarde HK$ 1.50B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.8 jaar en 4.9 jaar.

Belangrijke informatie

Ting Xu

Algemeen directeur

CN¥6.9m

Totale compensatie

Percentage CEO-salaris	95.2%
Dienstverband CEO	15.9yrs
Eigendom CEO	33.0%
Management gemiddelde ambtstermijn	5.8yrs
Gemiddelde ambtstermijn bestuur	4.9yrs

Recente managementupdates

Recent updates

Alphamab Oncology (HKG:9966) Stocks Shoot Up 91% But Its P/S Still Looks Reasonable

Sep 30

Some Alphamab Oncology (HKG:9966) Shareholders Look For Exit As Shares Take 48% Pounding

Jun 20

Alphamab Oncology's (HKG:9966) Shares Climb 27% But Its Business Is Yet to Catch Up

May 06

Optimistic Investors Push Alphamab Oncology (HKG:9966) Shares Up 27% But Growth Is Lacking

Mar 13

Subdued Growth No Barrier To Alphamab Oncology's (HKG:9966) Price

Jan 17

Slammed 40% Alphamab Oncology (HKG:9966) Screens Well Here But There Might Be A Catch

May 21

Newsflash: Alphamab Oncology (HKG:9966) Analysts Have Been Trimming Their Revenue Forecasts

Mar 01

Analyse CEO-vergoeding

Hoe is Ting Xu's beloning veranderd ten opzichte van Alphamab Oncology's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-CN¥216m
Mar 31 2024	n/a	n/a	-CN¥213m
Dec 31 2023	CN¥7m	CN¥7m	-CN¥211m
Sep 30 2023	n/a	n/a	-CN¥214m
Jun 30 2023	n/a	n/a	-CN¥218m
Mar 31 2023	n/a	n/a	-CN¥272m
Dec 31 2022	CN¥7m	CN¥6m	-CN¥326m
Sep 30 2022	n/a	n/a	-CN¥309m
Jun 30 2022	n/a	n/a	-CN¥292m
Mar 31 2022	n/a	n/a	-CN¥352m
Dec 31 2021	CN¥7m	CN¥5m	-CN¥412m
Sep 30 2021	n/a	n/a	-CN¥502m
Jun 30 2021	n/a	n/a	-CN¥592m
Mar 31 2021	n/a	n/a	-CN¥510m
Dec 31 2020	CN¥5m	CN¥4m	-CN¥428m
Sep 30 2020	n/a	n/a	-CN¥652m
Jun 30 2020	n/a	n/a	-CN¥877m
Mar 31 2020	n/a	n/a	-CN¥851m
Dec 31 2019	CN¥5m	CN¥3m	-CN¥833m

Compensatie versus markt: De totale vergoeding ($USD 979.81K ) Ting } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 410.05K ).

Compensatie versus inkomsten: De vergoeding van Ting is gestegen terwijl het bedrijf verliesgevend is.

CEO

Ting Xu (51 yo)

15.9yrs

Tenure

CN¥6,877,000

Compensatie

Dr. Ting Xu, Ph D., serves Chief Executive Officer at Alphamab Oncology since October 1, 2018. He Founded Alphamab Oncology in November 2008.Dr. Xu serves as Executive Director at Alphamab Oncology since...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ting Xu	Founder	15.9yrs	CN¥6.88m	33.05% CN¥ 1.4b
Yang Liu	VP of Corporate Operations & Executive Director	6yrs	CN¥2.97m	geen gegevens
Jin'nan Wang	Director of Investor Relations & Joint Company Secretary	3.8yrs	geen gegevens	geen gegevens
Yumin Wan	Vice President of Government Affairs & Public Relations	5.8yrs	geen gegevens	geen gegevens
Mike Liu	Senior Vice President of Business Development	6.4yrs	geen gegevens	geen gegevens
Jing Han	Chief Commercial Officer	2.9yrs	geen gegevens	geen gegevens
Lok Yee Chan	Joint Company Secretary	4.3yrs	geen gegevens	geen gegevens

5.8yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 9966 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ting Xu	Founder	6.6yrs	CN¥6.88m	33.05% CN¥ 1.4b
Yang Liu	VP of Corporate Operations & Executive Director	6yrs	CN¥2.97m	geen gegevens
Cheng Wei	Independent Non-Executive Director	4.9yrs	CN¥396.00k	geen gegevens
Jason J. Luke	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Yiping Yang	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Dong Wu	Independent Non-Executive Director	4.9yrs	CN¥396.00k	geen gegevens
Lei Zheng	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Zihai Li	Chairman of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Zijian Guo	Independent Non-Executive Director	3.2yrs	CN¥378.00k	geen gegevens

4.9yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 9966 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.9 jaar).

Alphamab Oncology Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

Alphamab Oncology, Annual General Meeting, Jun 12, 2024

Alphamab Oncology Resignation of Xu Zhan Kevin as Non-Executive Director and Member of the Strategy Committee

Alphamab Oncology Announces Board and Committee Changes

Alphamab Oncology, Annual General Meeting, Jun 10, 2022

Alphamab Oncology, Annual General Meeting, Jun 10, 2022

Recent updates

Alphamab Oncology (HKG:9966) Stocks Shoot Up 91% But Its P/S Still Looks Reasonable

New major risk - Share price stability

First half 2024 earnings released: CN¥0.047 loss per share (vs CN¥0.042 loss in 1H 2023)

Alphamab Oncology Presented the Latest Clinical Data from Two Studies on Anti-Her2 Bispecific Adc Jskn003 At the Esmo Congress 2024

Alphamab Oncology Announces Updates in Relation to A Phase III Clinical Trial of KN046 for the Treatment of Advanced SQ NSCLC

Insufficient new directors

Alphamab Oncology (SEHK:9966) commences an Equity Buyback Plan for 96,492,380 shares, representing 10% of its issued share capital, under the authorization approved on June 12, 2024.

Alphamab Oncology (SEHK:9966) commences an Equity Buyback Plan for 96,492,380 shares, representing 10% of its issued share capital, under the authorization approved on June 12, 2024.

First half 2024 earnings released: CN¥0.047 loss per share (vs CN¥0.042 loss in 1H 2023)

Alphamab Oncology to Report First Half, 2024 Results on Aug 15, 2024

Some Alphamab Oncology (HKG:9966) Shareholders Look For Exit As Shares Take 48% Pounding

Alphamab Oncology Presents Chinese Clinical Data of Anti-HER2 Bispecific ADC JSKN003 for the First Time at the 2024 ASCO Annual Meeting

Alphamab Oncology Provides Updates in Relation to A Phase III Clinical Trial of KN046 for the Treatment of Advanced PDAC

New major risk - Share price stability

Alphamab Oncology Announces First Patient Has Been Successfully Dosed in A Phase I Clinical Trial of JSKN016

Alphamab Oncology's (HKG:9966) Shares Climb 27% But Its Business Is Yet to Catch Up

Alphamab Oncology Announces Updates on Results of a Phase I Clinical Trial of JSKN003 for the Treatment of HER2-Expressing Advanced Solid Tumors for Presentation at 2024 AACR Annual Meeting

Alphamab Oncology Presented the Dose-Escalation Results from Jskn003 in Patients with Advanced/Metastatic Solid Tumors At Aacr

New minor risk - Share price stability

Consensus revenue estimates decrease by 12%, EPS upgraded

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

Alphamab Oncology, Annual General Meeting, Jun 12, 2024

Alphamab Oncology Announces the First Patient Dosed in Australia in the Clinical Study of Subcutaneous Formulation JSKN033

Alphamab Oncology Announces Results of Phase II Clinical Study of Kn046 Plus Chemotherapy as First-Line Treatment for Metastatic Nsclc Were Published in Cell Reports Medicine

Alphamab Oncology to Report Fiscal Year 2023 Results on Mar 28, 2024

Optimistic Investors Push Alphamab Oncology (HKG:9966) Shares Up 27% But Growth Is Lacking

Alphamab Oncology Announces Results of Phase II Clinical Study of KN046 in Combination with Nab-paclitaxel in TNBC were Published in Nature Communications

Subdued Growth No Barrier To Alphamab Oncology's (HKG:9966) Price

Alphamab Oncology Announces Phase I/II Clinical Trial of Jskn033 Independently Developed by Group for the Treatment of Human Epidermal Growth Factor Receptor

Alphamab Oncology Announces First Patient Dosed in Phase Iii Study of Jskn003 for the Treatment of Advanced Her2-Low Breast Cancer

Alphamab Oncology Announces Preliminary Results of a Phase I Clinical Trial of JSKN003 in Australia for the Treatment of Her2-Expressing Advanced Solid Tumors

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. Jointly Receive Breakthrough Therapy Designation on KN026 by CDE

Alphamab Oncology Announces Results of Two Studies of HER2 Bispecific Antibody KN026 At the European Society of Medical Oncology

New minor risk - Profitability

First half 2023 earnings released: CN¥0.042 loss per share (vs CN¥0.16 loss in 1H 2022)

Alphamab Oncology Announces Research Updates on KN046 and KN026 for Presentation At ESMO Congress 2023

Alphamab Oncology to Report First Half, 2023 Results on Aug 23, 2023

Alphamab Oncology Announces First Patient Successfully Dosed in Randomized, Controlled, Open-Label, Multi-Center, Phase III Clinical Trial of Kn026 in China

Alphamab Oncology Resignation of Xu Zhan Kevin as Non-Executive Director and Member of the Strategy Committee

Alphamab Oncology Updates Clinical Research Data for Kn026 in Combination with Kn046 in Her2-Positive Solid Tumors At the Asco 2023 Annual Meeting

Slammed 40% Alphamab Oncology (HKG:9966) Screens Well Here But There Might Be A Catch

Alphamab Oncology Updates in Relation to A Phase Iii Clinical Trial of Kn046 for the Treatment of Advanced SQ NSCLC

Consensus revenue estimates decrease by 13%, EPS upgraded

No longer forecast to breakeven

Newsflash: Alphamab Oncology (HKG:9966) Analysts Have Been Trimming Their Revenue Forecasts

Consensus revenue estimates decrease by 15%

Alphamab Oncology has completed a Follow-on Equity Offering in the amount of HKD 380.5 million.

Forecast to breakeven in 2025

Alphamab Oncology Presents Clinical Data of Kn026 Combined with Docetaxel as Neoadjuvant Treatment for Her2-Positive Early or Locally Advanced Breast Cancer At Sabcs 2022

Alphamab Oncology Presented Final Analysis of KN046 Combined with Nab-paclitaxel in the Treatment of mTNBC at SABCS 2022

Alphamab Oncology Announces Results from Three Clinical Studies of KN026 and KN046

Alphamab Oncology Receives IND Approval by NMPA for A Phase Ia/Ib Clinical Trial of JSKN003 for the Treatment of Advanced Solid Tumors

Is Alphamab Oncology (HKG:9966) Using Debt Sensibly?

Alphamab Oncology Announces First Patient Dosed in A Phase I Clinical Trial of JSKN003 (KN026-ADC) in Australia for the Treatment of Advanced Solid Tumors

Alphamab Oncology Presents the updated data from Phase 2 Clinical trial on KN046 Combined with platinum doublet chemotherapy as first-line(1L)treatment for NSCLC at ESMO 2022

Alphamab Oncology Announces Updates on Clinical Data of KN046 and KN026

Alphamab Oncology Announces Updates on Clinical Data of KN046 and KN026

Alphamab Oncology to Report First Half, 2022 Results on Aug 31, 2022

Alphamab Oncology Announces First Patient Dosed in Phase II Clinical Trial of KN046 Combined with Axitinib for the First-Line Treatment of Advanced NSCLC

Alphamab Oncology Announces Board and Committee Changes

Alphamab Oncology Announces First Patient Dosed in Phase I Trial of PD-L1/OX40 Bispecific Antibody KN052

Alphamab Oncology Announces First Patient Dosed in A Phase Ii Clinical Trial of Kn026 Combined with Palbociclib and Fulvestrant for the Treatment of Locally Advanced Unresectable or Metastatic Her2-Positive Breast Cancer

Is Alphamab Oncology (HKG:9966) A Risky Investment?

No longer forecast to breakeven

Alphamab Oncology Updates on Clinical Data of Kn046 in Combination with Kn026 for the Treatment of Her2-Positive Solid Cancer for Presentation at 2022 AACR Annual Meeting

No longer forecast to breakeven